leadf
logo-loader
RNS
viewFrontier IP Group PLC

Frontier IP Group - Cambridge Raman participates in EUR 5m project

RNS Number : 9829G
Frontier IP Group plc
01 December 2020
 

REACH

AIM: FIPP

01 December 2020

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Cambridge Raman Imaging participates in 5 million project to develop breakthrough medical imaging technology

 

Frontier IP, a specialist in commercialising intellectual property, today announces that portfolio company Cambridge Raman Imaging Limited (the "Company") is part of CRIMSON, a €5 million pan-European project to develop bio-photonic cell and tissue imaging technology to understand in greater depth the cellular origins of diseases. A full text of the CRIMSON release is below.

The technology combines advanced laser techniques and artificial intelligence to show how diseases unfold in cells and tissue at a molecular level in near real time. Initial applications include a microscope aimed at biomedical researchers, with initial validation work focused on cancer.

Over the next three-and-a-half years, CRIMSON aims to develop devices that are faster and more accurate than existing technologies to provide highly-detailed digital images of cells and tissue. The speed of the technology will allow researchers to use time-lapse imaging to observe how cells change when affected by disease without the presence of a dye or other chemicals.

Cambridge Raman Imaging is one of a 10-strong consortium involved in the project. The project is being led by its partner, the Politecnico di Milano, which has recognised the Company's Italian subsidiary Cambridge Raman Imaging s.r.l. as an official spin out. The Company's budget in the project amounts to €468,312 and its role will be to commercialise the technology for use in a microscope. Frontier IP owns a 25.8 per cent equity stake in Cambridge Raman Imaging.

In July 2020, Frontier IP announced the Company had raised £250,000 from private investors, valuing it at £1.5 million. The investment is supporting development of its graphene-based ultrafast laser technology for use in a medical microscope to diagnose and track tumours, and other detection applications.

 

Frontier IP Chief Executive Officer Neil Crabb said: "CRIMSON is looking to develop technology that could transform how biomedical researchers investigate the cellular origins of diseases, including cancer. Cambridge Raman Imaging's involvement in this prestigious project is strong validation of its expertise." 

 

 

CRIMSON statement begins:

European consortium to build next-generation microscope
promising to revolutionize the study of the cellular origin of diseases.

A breakthrough in microscopy and endoscopy will soon revolutionize the study of the cellular origin of diseases, advancing the field of precision medicine. This is the goal of CRIMSON, a trans-disciplinary and trans-national research project recently funded by European Commission. It will develop the next-generation bio-photonics imaging device for biomedical research, combining advanced laser techniques with artificial-intelligence data analysis. This groundbreaking microscope will provide three-dimensional quantitative maps of sub-cellular compartments in living cells and organoids and enable fast tissue classification with unprecedented biomolecular sensitivity. High acquisition speed will allow the observation of intra and inter-cellular dynamic changes by time-lapse imaging.

The CRIMSON project, starting 1 December 2020, lasting 42 months and with a budget exceeding 5M€, will also simulate future in-vivo studies and demonstrate the capability to image inside the body, realizing an innovative endoscope and applying it to ex-vivo thick tissue samples. The results have potentially profound societal impacts, improving patients' quality of life and reducing public healthcare costs.

A multidisciplinary team of world-leading organizations with vertical integration of all required skills composes the consortium, coordinated by Politecnico di Milano (Italy). Three research centers (Politecnico di Milano - Italy, Leibniz Institute of Photonic Technology e.V - Germany and Centre National de la Recherche Scientifique - France), with long-standing expertise in photonics, spectroscopy and nonlinear microscopy, will develop the technology. Three biomedical partners (Istituto Nazionale Tumori - Italy, Institut National de la Santé et de la Recherche Médicale - France and Jena University Hospital - Germany) will validate the imaging system on open biological questions related to cancer, as typical examples of the complexity and heterogeneity of cellular diseases.

Four innovative SMEs (Active Fibre Systems GmbH - Germany, Lightcore Technologies - France, Cambridge Raman Imaging Limited - UK and 3rdPlace S.r.l. - Italy), including a biomedical equipment manufacturer, will commercially exploit the innovation, thus creating a competitive advantage in the European biophotonics-related market for microscopes and R&D tools.

More info on www.crimson-project.eu 

 

 

CRIMSON statement ends 

 

ENquiries

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / James Hornigold

 

 

ABout frontier IP

Frontier IP unites science, finance and industry by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.   Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFDSFISESSELF

Quick facts: Frontier IP Group PLC

Price: -

Market: AIM
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Frontier IP Group PLC chief sees first investee IPO by the end of 2017

Neil Crabb, chief executive of Frontier IP Group PLC (LON:FIPP) says a number of its investee companies “are beginning to see significant commercial traction now.” In terms of an upcoming IPO for any of its investee firms, he says: “There are a number of companies in the portfolio...

on 03/09/2016

6 min read